Novo Nordisk expects to cover demand for obesity drug in 2022
It will take time before Novo Nordisk can keep up with the demand for obesity drug Wegovy, launched in the US in June. The supply issue is our top priority, says the CEO.
.jpg)
By Christopher Due Karlsson, translated by L. N. Barnes
The demand for obesity drug Wegovy in the US has taken Novo Nordisk by surprise, and the pharmaceutical company is struggling to keep up, acknowledged CEO Lars Fruergaard Jørgensen in the second quarter report released a few weeks ago.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades guidance for the rest of the year
For subscribers
.jpg&w=384&q=75)
